This article was originally published in Start Up
The founders of TheraCardia Inc. recognized that there was a missing link in the cardiac resuscitation chain and set about to develop a device that could provide temporary but effective circulatory support for victims of sudden cardiac arrest, both in the pre-hospital and hospital settings. The company has developed a device that can accomplish direct cardiac massage in a minimally invasive manner.
You may also be interested in...
Bioabsorbable stents arouse great enthusiasm among both interventionalists and industry executives, because they have one major advantage over current stents, both bare metal and drug-eluting: they obviate the need for a permanent implant when only a temporary scaffolding effect is needed. Many stent companies are hedging their bets, working on stents that incorporate both drug elution and bioabsorbability--but not Paris-based Arterial Remodeling Technologies, which is arguing that natural healing, not drug therapy, is the best approach to therapeutically active stents.
A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group, "The Eyes Still Have It," features profiles of Alacrity Biosciences, Eyeon Therapeutics, Mobius Therapeutics and OcuCure Therapeutics. Plus these Start-Ups Across Health Care: CyberHeart, GlycoVaxyn, TheraCardia and Vicus Therapeutics.
Two top officials in the US FDA’s device center are warning of delays in the agency’s review of submissions for new products that aren’t directly tied to the coronavirus pandemic.